Trials / Completed
CompletedNCT01965080
Exemestane in Advanced and Recurrent Endometrial Carcinoma
Phase 2 Study of Exemestane in Advanced and Recurrent Endometrial Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase II study of Exemestane in Advanced or recurrent endometrial carcinoma Hypothesis: Treatment With Exemestane can give a response rate of at least 30%
Detailed description
Patients With Advanced or recurrent endometrial cancer of endometrioid type were treated With Exemestane tablets 25 mg daily. Patients were grouped according to estrogen receptor status.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Exemestane | One tablet Exemestane 25 mg daily |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2013-10-18
- Last updated
- 2013-10-18
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT01965080. Inclusion in this directory is not an endorsement.